Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma | Zendy

Deepesh Lad | Zendy; Pankaj Malhotra | Zendy; Amol Patil | Zendy; Ram Vasudevan Nampoothiri | Zendy; Kripa Shanker Kasudhan | Zendy; Alka Khadwal | Zendy; Gaurav Prakash | Zendy; Arihant Jain | Zendy; Samir Malhotra | Zendy; Neelam Varma | Zendy; Savita Verma Attri | Zendy; Subhash Varma | Zendy

Open Access

Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma

Author(s) -

Deepesh Lad,

Pankaj Malhotra,

Amol Patil,

Ram Vasudevan Nampoothiri,

Kripa Shanker Kasudhan,

Alka Khadwal,

Gaurav Prakash,

Arihant Jain,

Samir Malhotra,

Neelam Varma,

Savita Verma Attri,

Subhash Varma

Publication year - 2020

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2020.06.002

Subject(s) - innovator , melphalan , multiple myeloma , hematopoietic cell , term (time) , medicine , oncology , haematopoiesis , transplantation , hematopoietic stem cell transplantation , computer science , stem cell , biology , intellectual property , genetics , operating system , physics , quantum mechanics

Most data on autologous hematopoietic cell transplantation (auto-HCT) in myeloma are based on the use of innovator formulation of melphalan. Comparative bioequivalence and efficacy studies of generic melphalan are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research